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Abstract
Recent epidemiological studies, basic research and clin-
ical trials on colorectal cancer (CRC) prevention have 
helped identify candidates for effective chemopreven-
tive drugs. However, because of the conflicting results 
of clinical trials or side effects, the effective use of che-
mopreventive drugs has not been generalized, except 
for patients with a high-risk for developing hereditary 
CRC. Advances in genetic and molecular technologies 
have highlighted the greater complexity of carcino-
genesis, especially the heterogeneity of tumors. We 
need to target cells and processes that are critical to 
carcinogenesis for chemoprevention and treatment of 
advanced cancer. Recent research has shown that in-
testinal stem cells may serve an important role in tumor 
initiation and formation of cancer stem cells. Moreover, 
studies have shown that the tumor microenvironment 
may play additional roles in dedifferentiation, to enable 
tumor cells to take on stem cell features and promote 
the formation of tumorigenic stem cells. Therefore, 
early tumorigenic changes of stem cells and signals for 
dedifferentiation may be good targets for chemopre-
vention. In this review, I focus on cancer stem cells in 
colorectal carcinogenesis and the effect of major che-
mopreventive drugs on stem cell-related pathways.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: To develop optimal chemopreventive agents, 
we need to target cells and pathways that are essential 
and critical to carcinogenesis: early tumorigenic chang-
es of stem cells and signals for dedifferentiation may 
be good targets for chemoprevention. Major chemopre-
ventive drugs, such as non-steroidal anti-inflammatory 
drugs, statins, proliferator-activated receptor γ agonists 
and metformin, have cancer stem cell (CSC)-suppress-
ing effects via regulation of stem cell-regulating path-
ways, stem cell niche in the tumor microenvironment, 
and altered tumor metabolism. These stem cell-related 
steps in tumorigenesis could be critical targets for che-
moprevention and CSC-targeted adjunctive treatment 
of colorectal cancer.
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CHEMOPREVENTIVE DRUGS FOR 
COLORECTAL CANCER AND FUTURE 
DIRECTION 
Colorectal cancer (CRC) is one of  the most commonly 
diagnosed cancers, and is a major cause of  cancer mor-
bidity and mortality worldwide[1]. Although there have 
been improvements in surgical and oncological therapies, 
the data have shown limited survival improvements in 
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advanced CRC[2]. Therefore, prevention strategies remain 
the most promising avenue for reducing both the inci-
dence and mortality of  CRC. 
CRC development is a multi-step process that oc-
curs over a span of  about 10 years, thereby providing an 
opportunity for prevention and early detection[3]. CRC 
screening and polyp removal are effective interventions 
for CRC prevention[3,4]. However, along with screening 
efforts, we need a specific prevention strategy for pa-
tients at high-risk for developing CRC. Chemoprevention 
involves the use of  a variety of  agents that can prevent, 
delay, or even reverse the development of  pre-malignant 
lesions by suppressing the multi-step carcinogenic pro-
cess. Many studies have demonstrated that pre-malignant 
lesions can be reversed and prevented pharmacologi-
cally[5]. This effect is of  particular importance to high-risk 
individuals with a hereditary predisposition for or suscep-
tibility to the environmental causes of  CRC. Chemopre-
vention shows great promise in this regard and the ideal 
chemopreventive agent, with an excellent safety profile, 
remains to be discovered.
Until now, there have been several major candidates 
for CRC chemopreventive drugs, including aspirin and 
non-steroidal anti-inflammatory drugs (NSAIDs), statins, 
peroxisome proliferator-activated receptor (PPAR) γ 
agonist, and metformin, which exhibit chemopreventive 
effects in epidemiologic studies, in in vitro and in vivo ex-
periments, and in some clinical trials. 
NSAIDs have received the most attention as chemo-
prevention agents in CRC, and experimental and clinical 
studies have consistently shown that NSAIDs may reduce 
the risk of  colorectal adenoma or cancer[6,7]. In experi-
mental models, either nonselective or cyclooxygenase-2 
(COX2)-selective NSAIDs have been shown to suppress 
CRC growth through COX2-dependent and -indepen-
dent mechanisms, such as activation of  apoptotic and 
anti-inflammatory signals[8,9].
Many clinical trials have addressed the cancer-preven-
tive effect of  aspirin, using colorectal adenomas as a sur-
rogate primary end point for cancer, and the data support 
its benefits in reducing the risk of  CRC. In patients with 
a history of  a previous CRC[10] or a history of  colorectal 
adenomas[6,11], the recurrence of  adenoma was reduced in 
patients who received aspirin vs those who did not. In ad-
dition, in patients with hereditary non-polyposis CRC, the 
long-term use of  aspirin reduced the incidence of  CRC, 
with an HR of  0.63 (95%CI: 0.35-1.13)[12]. 
In addition to aspirin, other NSAIDs have also shown 
efficacy in CRC prevention trials. For example, in one 
clinical trial, in which patients with a history of  resected 
adenomas were randomized to receive either sulindac plus 
difluoromethylornithine or matched placebos, promising 
results were seen, in that the risk ratio was 0.30 (95%CI: 
0.18-0.49) for recurrent adenomas and 0.085 (95%CI: 
0.011-0.650) for advanced adenomas in the intervention 
arm relative to the placebo arm[13]. In addition, recent 
long-term follow-up studies have reported that NSAIDs 
may also reduce the recurrence and mortality of  CRC[14-16]. 
Meanwhile, celecoxib, a selective COX2 inhibitor, showed 
promise in inhibiting adenoma occurrence in familial 
adenomatous polyposis patients[17] and in patients with a 
history of  colorectal polyps[18,19]. However, COX2 selec-
tive inhibitors are no longer considered for prevention of  
CRC because of  their cardiovascular toxicities[20-22].
Statins, widely used cholesterol-lowering drugs, in-
hibit cholesterol synthesis via inhibition of  3-hydroxy-
3-methylglutaryl coenzyme A (HMGCoA) reductase, the 
rate-limiting enzyme in the mevalonate and cholesterol-
synthesis pathway. Many of  the downstream products of  
this pathway are required for critical cellular functions, 
such as maintenance of  membrane integrity, signaling, 
protein synthesis and cell cycle progression[23,24]. How-
ever, clinical studies examining the relationship between 
statins and CRC incidence have yielded mixed results. 
Although some case-control and cohort studies and a 
meta-analysis study[25-31] demonstrated a protective ef-
fect against CRC in statin users, other studies failed to 
do so[32-37]. Siddiqui et al[38] showed reduced recurrence 
of  polyps (OR = 0.51, 95%CI: 0.43-0.60) and high-risk 
polyps (OR = 0.74, 95%CI: 0.52-0.96), and diminished 
polyp size and number in patients who used statins con-
tinuously for up to 5 years. Moreover, statins have an 
excellent safety profile. To overcome the possible dis-
crepancies in the results from studies of  statins in CRC 
chemoprevention, a thorough analysis of  the underlying 
CRC risk, methodologies and exposure time are needed, 
along with data from well-designed large-scale clinical 
trials and epidemiological studies in the future. The exact 
role of  statins in chemoprevention remains to be eluci-
dated. In addition, recent data have suggested that statins 
may have beneficial effects on disease progression and 
survival, indicating that long-term use of  statins may be 
associated with a less-advanced tumor stage and a better 
survival rate[34,39].
PPARγ agonists, such as thiazolidinedione (TZD), an 
insulin-sensitizing diabetes drug, also have anti-cancer ac-
tivities, involving inhibition of  cell growth and induction 
of  apoptosis and terminal cellular differentiation[40-43]. 
PPARs have central roles in the regulation of  glucose 
and lipid homeostasis, and also regulate cell proliferation, 
differentiation, and inflammation[44]. Recently, several 
studies have reported that the use of  TZDs may be as-
sociated with a decreased risk of  CRC in patients with 
diabetes[45,46], and in some cases, PPARγ agonists have 
also shown modest efficacy for chemoprevention in clini-
cal trials[47,48]. In addition, PPARγ expression in CRC pri-
mary tumors correlates well with overall survival of  CRC 
patients[49], which is consistent with animal experiments 
showing that intestinal tumors are exacerbated in APC 
min/+ mice with genetic ablation of  Pparg, compared 
with control APC min/+ mice[50]. However, controversy 
regarding the anti-tumor effect of  PPARγ agonists per-
sists because some studies indicated that activation of  
PPARγ promotes tumorigenesis[51-54]. Furthermore, clini-
cal studies show that TZD may be associated with an 
increased risk of  heart failure[55], bone fractures[56-58] and 
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possibly bladder cancer[59]. Whether these are PPARγ-
mediated side effects or off-target effects remain uncer-
tain. Although PPARγ is currently considered a potential 
target for chemoprevention, previous results are based 
mainly on observational and preclinical studies, and rig-
orous clinical trials are needed to address the utility of  
PPARγ agonists in CRC chemoprevention. 
Metformin is a classic biguanide drug that has been 
used as first-line therapy for type 2 diabetes mellitus 
(DM). Metformin inhibits hepatic gluconeogenesis and 
reduces insulin resistance. It is a safe and economical 
drug that has been used for more than 50 years. Most 
CRC-specific observational studies and meta-analyses 
reported that patients with type 2 DM who were taking 
metformin have a lower risk of  CRC and better out-
comes compared with patients not taking the drug[60-64]. 
Moreover, metformin showed a protective effect for 
colorectal adenoma recurrence in colonoscopic surveil-
lance of  CRC patients with diabetes[65]. Preclinical stud-
ies in animal models support these findings, showing 
that metformin induced AMP-activated protein kinase 
(AMPK) activation and inhibited tumor development 
and growth, including colon tumorigenesis[66,67]. In terms 
of  its molecular mechanism, metformin regulates insu-
lin/insulin-like growth factor-related pathways, inflam-
matory activity, and the AMPK/mammalian target of  the 
rapamycin (mTOR) pathway[68]. Activated AMPK inhibits 
the mTOR-mediated synthesis of  key proteins respon-
sible for malignancy and growth of  cancer cells[69], and is 
thought to be a main mediator of  the potential anti-can-
cer mechanism of  metformin. Despite the promising re-
sults in these studies, data pertaining to metformin from 
well-designed clinical trials for CRC and its precancerous 
lesions are lacking. Furthermore, the anti-tumor effect 
of  metformin on non-diabetic patients should also be 
assessed, because the safety of  metformin is well known 
and it has no glucose-lowering effects in non-diabetic pa-
tients. One clinical trial demonstrated an inhibitory effect 
of  metformin in aberrant crypt foci formation of  the 
rectum in patients who did not have diabetes[70]. How-
ever, this study showed a short-term effect of  metformin 
in a small number of  subjects. Therefore, large-scale 
randomized controlled trials are required to confirm the 
chemopreventive and therapeutic effects of  metformin, 
especially for non-diabetic patients[71]. 
Among the most-promising chemopreventive drugs 
currently being studied, NSAIDs have consistently 
shown a protective effect against CRC; however, they 
are generally not recommended for widespread chemo-
prevention because of  the increased risk of  bleeding[72]. 
In addition, COX2-selective inhibitors showed increased 
cardiovascular morbidity[73]. However, statins, PPARγ 
agonists and metformin have a relatively good safety pro-
file, and these drugs show similarities in their abilities to 
improve metabolic disorders that are known to be associ-
ated with increased cancer risk, such as diabetes, obesity, 
dyslipidemias, and chronic inflammation. For widespread 
acceptance of  these chemopreventive drugs, more defi-
nite chemopreventive effects in large-scale well-designed 
clinical trials need to be demonstrated, along with a more 
acceptable safety profile for PPARγ agonists.
Future directions in CRC chemoprevention will in-
clude genetic and molecular approaches for identifying 
pathways that are associated with cancer initiation and 
development, and personalized approaches to predict 
risk, drug susceptibility and toxicity. In addition, mech-
anism-based combinations of  agents will also maximize 
effectiveness, while limiting drug toxicity. From the 
perspective of  identifying new targets for chemopreven-
tion, besides the traditional targeting of  the multi-step 
process in colorectal carcinogenesis, new evidence has 
demonstrated that targeting essential cell types and criti-
cal signaling pathways, such as tumor-initiating stem cells 
and stem cell-related pathways, could be another effective 
strategy for preventing colorectal tumorigenesis. 
STEM CELLS IN CRC AND EARLY 
CARCINOGENESIS: OPPORTUNITIES FOR 
CHEMOPREVENTION
Much evidence has shown that genomic instability, in-
cluding chromosomal and microsatellite instability, and 
epigenetic changes are important mechanisms for multi-
step tumorigenesis of  CRC[74]. However, we have come 
to understand that tumors show inter- and intra-tumoral 
heterogeneity, even in the same patient, and more com-
plex intercellular interactions. Therefore, we need to 
identify the cells and cellular interactions that are critical 
in tumors to eradicate cancer cells and prevent cancer 
development. Recent evidence revealed that stem cells, 
the tumor microenvironment and metabolic alterations 
are closely related and critical steps in colorectal carcino-
genesis. With recent advances in our understanding of  
the homeostatic control of  intestinal crypts and microen-
vironments (niches), we are able to delineate the steps in 
early carcinogenesis of  CRC, which could lead to devel-
opment of  new targets for chemoprevention of  CRC.
Within the crypts of  the intestinal mucosa, the in-
testinal epithelium is a permanently renewing tissue, the 
architecture of  which is maintained by the ability of  the 
intestinal stem cells to self-renew and generate a hierar-
chy of  proliferative and differentiated cells[75]. The bal-
ance between proliferation and cell death is important for 
homeostasis of  the intestinal epithelium. Using genetic 
lineage-tracing methods for stem cell markers, several 
markers of  intestinal stem cells, including B-lymphoma 
Mo-MLV insertion region 1 (BMI1), telomerase reverse 
transcriptase, leucine-rich repeat-containing G protein-
coupled receptor 5 (Lgr5), leucine-rich repeats and im-
munoglobulin-like domains 1 (Lrig1), olfactomedin 4 and 
achaete-scute complex homolog 2 (ASCL2), have been 
identified[76-80].
As for the stem cell niche or microenvironment, 
subepithelial mesenchymal cells, their secreted growth 
factors, and basement membrane factors that regulate 
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of  advanced CRC.
Effect and mechanisms of chemopreventive drugs on 
CSCs 
Recent evidence suggests interesting similarities in the 
effects of  the above-mentioned major chemopreventive 
drugs, such as aspirin, NSAIDs, statins, PPARγ agonists, 
and metformin; these include their CSC-suppressing ef-
fect, anti-inflammatory action, and regulation of  altered 
tumor metabolism. In addition, both anti-inflammatory 
effects and regulation of  altered tumor metabolism are 
also associated with the CSC-suppressing effects of  these 
drugs. 
CSCs are involved in tumor initiation, growth, recur-
rence, and metastasis; therefore, these data suggest that 
the preventive and survival-improving effects of  chemo-
preventive drugs on CRC might be related to their CSC-
suppressing ability. Therefore, in this section, I focus on 
the relationship between normal/cancer stem cell-related 
pathways and the mechanism of  the chemopreventive 
drugs.
Direct effect on stem cell and cancer stem cells via 
regulation of Wnt, NOTCH and BMP pathways
The anticarcinogenic activity of  NSAIDs in CRC may de-
pend mostly on the inhibition of  COX2 activity, because 
prostaglandins (PGs) play an important role in tumorigen-
esis in CRC[94-97]. COX2 is reported to be overexpressed in 
85% of  human CRC cases and in about 50% of  colorec-
tal adenomas[94], and was also identified in an animal mod-
el[97], in which a COX2 null mutation significantly reduced 
the number and size of  polyps in Apc∆716 mice[98]. An 
earlier study reported that COX2 over-expression leads 
to the production of  PGE2, which ultimately stimulates 
β-catenin-mediated transcription in colon cancer[99]. The 
WNT/β-catenin pathway is thought to be involved in the 
regulation of  CSCs, and is one of  the most interesting 
therapeutic targets in CSCs[100]. In terms of  the anti-CSC 
effect of  NSAIDs, Moon et al[101] showed that the anti-
CSC effects of  NSAIDs were related to both COX2-
dependent and -independent pathways. 
As traditional NSAIDs exert anticancer effects via 
COX2-independent mechanisms[102], the COX2-inde-
pendent pathways of  NSAIDs could be involved in their 
anti-CSC activity. In several previous reports, NSAIDs 
were shown to inhibit NOTCH/hairy and enhancer of  
split 1 (HES1) signaling pathway as a γ-secretase inhibi-
tor[103,104] and activate the PPARγ expression as a PPARγ 
agonist[105,106]. NOTCH/HES1 signaling has been shown 
to be oncogenic in CRCs, inhibiting the terminal dif-
ferentiation of  epithelial cells[107], and the dysregulation 
of  the NOTCH/HES1 signaling was implicated in the 
self-renewal and maintenance of  CSCs in CRC[108]. Mean-
while, PPARγ activation resulted in growth arrest and in-
duced differentiation of  colon cancer cells[45]. In addition, 
the CSC-inhibitory effect of  PPARγ agonists through the 
inhibition of  the Janus kinase-signal transducer and acti-
vator of  transcription (STAT) pathway was demonstrated 
epithelial cell function support the intestinal crypts. 
Pericryptal myofibroblasts (PCMFs), one of  the micro-
environment or niche components, have crucial func-
tions and roles in intestinal organogenesis, regulation of  
epithelial cell proliferation and differentiation, mucosal 
protection, wound healing and extracellular matrix 
(ECM) metabolism that affects the growth of  the base-
ment membrane[81,82]. In addition, many inflammatory 
cells, such as macrophages and lymphocytes, are also 
important components of  the microenvironment in both 
normal and pathological states. PCMFs and inflamma-
tory cells are located immediately beneath the basement 
membrane, just under the epithelial cells, and function 
through the secretion of  growth factors, cytokines and 
basement membrane/ECM proteins; they become acti-
vated through direct and indirect interactions[82]. Several 
studies showed that interstitial myofibroblasts and in-
flammatory cells increase in neoplastic lesions, suggesting 
that myofibroblasts and inflammatory cells play critical 
roles in colorectal neoplasia, as well as under normal 
conditions[83-85].
The stem/progenitor cells, transient amplifying cells, 
and, finally, the terminally differentiated cells in intestinal 
crypts are under homeostatic control through important 
signals, such as the Wnt, bone morphogenic protein 
(BMP), NOTCH, Hh and phosphoinositol 3-kinase 
(PI3K)/mTOR pathways[86]. The regulation of  these sig-
nals occurs via the tight control of  interactions between 
stem/progenitor cells and the niche microenvironment, 
such as the PCMFs, smooth muscle cells and inflamma-
tory cells[86]. The dysregulation of  cryptal homeostasis 
can induce tumorigenesis and the micro environmental 
factors secreted by inflammatory cells and myofibroblasts 
in tumors, as well as accumulation of  epithelial changes, 
have important roles in early tumor progression[86].
Recent evidence suggests that CRC may arise from 
mutated colorectal stem or progenitor cells that have 
been termed colorectal cancer stem cells (CSCs) or ini-
tiating cells because of  their exclusive ability to sustain 
tumor formation[87,88]. Colorectal CSCs have been iden-
tified based on the expression of  specific cell surface 
markers, such as cluster of  differentiation (CD)133, 
CD44, CD166, aldehyde dehydrogenase, doublecortin-
like kinase 1 (Dclk1), Lgr5 and Eph receptor B2, and 
these cells demonstrated stem/progenitor cell properties, 
in terms of  their ability to self-renew, differentiate, and 
proliferate indefinitely to drive continuous expansion of  
the malignant cell population[89-93]. These data empha-
size the importance of  better characterization of  CSCs, 
because the limited numbers of  CSCs within the bulk 
of  the tumor may account for their capability to escape 
conventional therapies, leading to relapse and metastasis. 
CSCs are now recognized as a specific target for the com-
plete elimination of  CRC (Figure 1). In addition, because 
these CSCs appear in the very early stages of  colorectal 
carcinogenesis, the early changes that occur in normal 
and cancer stem cells during carcinogenesis might be an 
effective target for chemoprevention, as well as treatment 
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in brain CSCs[109]. In this context, Moon et al[101] showed 
that the NOTCH pathway and PPARγ could be related 
to CSCs in CRC and be down- and up-regulated by 
NSAIDs, respectively, suggesting that NSAIDs suppress 
colon CSCs via COX2-independent pathways.
In addition, Qiu et al[110] demonstrated that sulindac 
induces apoptosis to remove the intestinal stem cells 
with aberrant Wnt signaling, and that diablo IAP-binding 
mitochondrial protein (also referred to as SMAC), a mi-
tochondrial apoptogenic protein, has a central role in 
this tumor-suppressive effect of  sulindac. These results 
suggested that the chemopreventive effect of  NSAIDs is 
mediated through the elimination of  stem cells that are 
inappropriately activated by oncogenic events.
Some natural chemopreventive dietary compounds, 
such as curcumin, sulforaphane and piperine, also have 
been shown to suppress CSCs through inhibition of  
WNT/β-catenin signaling[111-113].
Statins also have anti-CSC activity. Kodach et al[114] 
showed that tumor-suppressive BMP signaling was si-
lenced by promoter hypermethylation of  BMP2 in CRC, 
and downregulation of  DNA methyltransferase activity 
by statin led to BMP2 promoter demethylation and up-
regulation of  BMP2 expression, culminating in the dif-
ferentiation of  CRC cells and reduction of  “stemness”. 
Therefore, the suppression of  Wnt and NOTCH 
signaling, and activation of  BMP and PPARγ signaling 
that is induced by NSAIDs, statins, PPARγ agonists, and 
some natural chemopreventive dietary compounds might 
have potential effects on the fate of  stem cells, inducing 
cell differentiation, cell cycle arrest, and apoptosis.
Regulation of stem cell niche and the inflammatory 
nuclear factor-κB pathway
Recent studies show that bidirectional conversion be-
tween CSCs and non-CSCs can be triggered by stromal 
factors secreted by inflammatory cells or myofibroblasts 
in the tumor microenvironment[115,116]. These factors en-
hance Wnt activation, induce dedifferentiation of  non-
stem cells and expand stem cell properties during tumori-
genesis. In this regard, the anti-inflammatory effect of  
chemopreventive drugs can retard this de-differentiating 
effect.
As an important component of  the tumor microen-
vironment, chronic inflammation is also a key factor in 
the progression of  many cancers. Nuclear factor (NF)-
κB represents a key transcription factor within the in-
flammatory tumor microenvironment. Schwitalla et al[116] 
demonstrated NF-κB’s function in CSCs, showing that 
elevated NF-κB signaling enhances Wnt activation and 
induces de-differentiation of  non-stem cells that have ac-
quired a tumor-initiating capacity. Subsequently, epithelial 
cell-specific ablation of  the RelA/p65 subunit of  NF-κB 
retards crypt stem cell expansion; these data support the 
Figure 1  Role of cancer stem cell and anti-cancer stem cell therapy in colorectal cancer. The limited numbers of cancer stem cell (CSC) within the bulk of the tumor 
may account for their capability to escape conventional therapies, leading to relapse and metastasis; therefore, CSCs are now recognized as a specific target for the com-
plete elimination of colorectal cancer. CSCs are resistant to conventional chemotherapy: the tumor is reduced in size in the short term, but eventually relapses, driven by 
CSCs. When CSC-targeted therapy or CSC-differentiating therapy is combined with conventional therapy, a tumor will progressively exhaust its growth potential. 
Cancer stem cell
Proliferating cell
Differentiated cell
Differentiating progenitor cell
CSC-targeted therapy
Conventional cytotoxic 
chemotherapy
Differentiation therapy
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concept of  bidirectional conversion and the importance 
of  inflammatory signaling for de-differentiation and gen-
eration of  CSCs[116].
Metformin inhibits initial cellular transformation and 
selectively suppresses CSCs by inhibition of  NF-κB and 
STAT3[117]. In addition, metformin reduces inflammatory 
responses via inhibition of  tumor necrosis factor (TNF)-
production in human monocytes[118], and metformin-
induced AMPK signaling inhibits the NF-κB-mediated 
inflammatory responses[119]. Thus, metformin may target 
the inflammatory processes in the microenvironment of  
most neoplastic tissues and cancer cells[117,119].
Similarly, PPARγ agonists can attenuate NF-κB-
dependent signaling and induce downregulation of  pro-
inflammatory target genes, such as TNF and interleu-
kin-6[120], and statins also reduce colon tumorigenesis via 
their potential anti-inflammatory and immunomodulatory 
properties[121,122]. In addition, the anti-inflammatory action 
of  NSAIDs is already well established. All the major che-
mopreventive drugs discussed in this review have anti-
inflammatory properties, which suggest their association 
with anti-CSC activity through an anti-inflammatory 
action on the tumor microenvironment, along with their 
direct effects on CSCs. 
Vermeulen et al[115] demonstrated that myofibroblast-
secreted factors, specifically hepatocyte growth factor, 
activate β-catenin-dependent transcription and subse-
quently CSC clonogenicity, indicating that Wnt activity 
and cancer stemness are regulated by microenvironmen-
tal factors. They also showed that myofibroblast-secreted 
factors restore the CSC phenotype in more differentiated 
cells, suggesting the dynamic bidirectional conversion of  
stemness of  colon cancer cells[115]. 
Currently, the regulation of  microenvironmetal fac-
tors has become one of  the major targets for develop-
ment of  anti-CSC drugs, and they could be important 
targets for chemoprevention as well, because the stem 
cell niche is involved in the very early stages of  tumori-
genesis.
Regulation of altered tumor metabolism and the AMPK/
mTOR pathway
In terms of  cancer metabolism, recent evidence reveals 
that metabolic alterations and reprogramming of  cancer 
cells are not indirect responses to cell proliferation, but 
altered metabolism itself  can be tumorigenic by changing 
cell signaling and blocking cellular differentiation[123]. 
The AMPK/mTOR pathway is a central cellular en-
ergy sensor[124]. Liver kinase B1 (LKB1), the upstream 
activator of  AMPK, is a tumor suppressor, and the major 
pathway controlled by LKB1-AMPK activation is the 
mTOR signaling pathway, which regulates cell growth 
and proliferation[124,125]. Activation of  AMPK led to in-
hibition of  the mTOR through phosphorylation and 
subsequent activation of  the tumor suppressor tuberous 
sclerosis complex 2. mTOR is a key regulator of  growth 
factor and nutrient signals, as well as a critical mediator 
of  the PI3K/protein kinase B/Akt pathway, one of  the 
most frequently dysregulated signaling pathways in hu-
man cancer[124,126].
In preclinical studies, metformin induced tumor 
suppression through mTOR inhibition by AMPK ac-
tivation[127]. In addition, activation of  the Akt/mTOR 
pathway has been associated with malignant progression, 
resistance to many types of  cancer therapy and poor 
prognosis[126]. The PI3K/Akt/mTOR pathway has, there-
fore, recently been identified as a target for novel cancer 
therapy, and the inhibition of  mTOR signaling is thought 
to be one of  the major mechanisms involving the anti-
cancer effect of  metformin. Activation of  AMPK also 
induces cell cycle arrest by inhibiting the expression of  
cyclin D1 and activating p21/p27, resulting in cellular se-
nescence, quiescence, and apoptosis[128,129].
Recent studies have demonstrated that metformin 
could selectively suppress cancer stem cells using in vitro 
experiments and in vivo xenograft models[117,130,131]. Met-
formin has also been shown to improve tumor response 
to chemotherapy, by activating a cytotoxic effect on 
CSCs that exhibit chemoresistant features[117,130,132]. The 
PI3K/Akt/mTOR pathway is activated for maintenance 
and proliferation of  CSCs[133-135]; therefore, the mecha-
nism of  action of  metformin-induced CSC suppression 
involves the activation of  AMPK and the consequent 
inactivation of  mTOR. CSCs are known to be resistant 
to conventional chemotherapy, and are a cause of  cancer 
recurrence and metastasis; therefore, metformin’s effect 
of  eliminating cancer stem cells suggest the possibility of  
metformin as an adjunctive agent combined with conven-
tional chemotherapy, as well as a chemopreventive drug. 
Moreover, aspirin, statin, and PPARγ agonists also 
induce the activation of  AMPK, targeting regulators of  
intracellular energy homeostasis and metabolism[136-140]. 
These could contribute to their protective effects against 
development of  CRC.
CONCLUSION
Candidates for effective CRC chemopreventive drugs 
have been identified through epidemiological studies, 
basic research and clinical trials. However, to develop 
more effective chemopreventive drugs with good safety 
profiles, we need to target cells and pathways that are es-
sential and critical to carcinogenesis, along with targeting 
the traditional multi-step process of  CRC tumorigenesis.
With recent advances in our understanding of  intesti-
nal crypt homeostasis and its dysregulation, mutated stem 
cells and CSCs in early carcinogenesis are likely to be 
promising targets for chemoprevention of  CRC. How-
ever, to target the CSCs and stem cell-specific signaling 
pathways in early carcinogenesis, a detailed understanding 
of  the mechanisms of  stem cell maintenance and dif-
ferentiation, and their relationship with the carcinogenic 
pathways is needed.
Several recent reports indicate that major chemo-
preventive drugs like aspirin, NSAIDs, statins, PPARγ 
agonists, and metformin have CSC-suppressing effects 
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via regulation of  stem cell-regulating pathways (Wnt, 
NOTCH, and BMP), stem cell niche or tumor micro-
environment (inflammatory NF-κB and stromal factor-
induced Wnt pathways) and altered tumor metabolism 
(AMPK/mTOR pathway) (Figure 2).
Changes in the stem cells, microenvironment, and 
metabolism are closely related, underlying essential steps 
in early carcinogenesis and tumor progression, and could 
be critical targets for chemoprevention and treatment of  
CRC (Figure 2). In addition to being more effective anti-
neoplastic and chemopreventive drugs, either alone or in 
combination with other agents, these chemopreventive 
drugs could also be the basis for development of  chemi-
cally modified drugs with better chemopreventive activity 
and a more desirable safety profile.
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